AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative
advanced therapies for some of the world’s most complex and critical conditions, such as hidradenitis suppurativa.
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative
advanced therapies for some of the world’s most complex and critical conditions, such as hidradenitis suppurativa.
Welcome to the 13th edition of the European Hidradenitis Suppurativa Foundation Conference in Lyon!
With the emergence of innovative biologics, combined with surgical strategies, the HS community is undergoing a remarkable revolution. The EHSF is the congress to discuss cutting edge data and emergent therapeutic strategies in HS; with the latest revelations in clinical and fundamental research, or the most ardent debates on diagnostic and treatments.
There is indeed still so much to be done to improve the care of HS patients! This meeting will be a wonderful opportunity for scientists, caregivers and patients to connect in a multidisciplinary hub.
With Lyon hosting the EHSF, attendees will enjoy exciting social programs, the warmest hospitality, and the most exquisite traditional French cuisine.
We are delighted and honored to host the 13th EHSF in Lyon, eagerly anticipating your passionate response to these fundamental issues.
Axel VILLANI, MD, PhD
Professor
Philippe GUILLEM, MD, PhD
Prof. Dr. med. Christos C. Zouboulis is Director of the Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Germany, Founding University Professor of Dermatology, Venereology and Allergology at the Brandenburg Medical School Theodor Fontane and Co-opted Professor of Dermatology and Venereology at the Faculty of Health Sciences Brandenburg, Germany.
He is also elected Professeur honoraire at the Medical Faculty, University of Franche-Comté, Besançon, France, Dr. h.c. of the National and Kapodistria University of Athens, Greece, and Visiting Professor of the Shanghai Jiao Tong Medical University, China.
He serves as President of the European Hidradenitis Suppurativa Foundation (EHSF) e.V., Board member of the European Academy of Dermatology and Venereology (EADV) and coordinator of the EADV Task Force on Acne, Rosacea and Hidradenitis Suppurativa (ARHS), Executive Committee Member of the International Society on Behçet’s Disease, President of the Section Saxony-Anhalt of the Federation of German Allergologists, and Honorary President of the European Society of Preventive, Regenerative and Anti-Aging Medicine (ESAAM), and Executive Council member of the Faculty of Health Sciences Brandenburg.
He is currently Editor of EADV News, Co-Editor of “Rejuvenation Research” and member of the Editorial Boards of several leading international scientific journals. He is a honorary member of the French Dermatological Society, the Hungarian Dermatological Society, the Italian Society of Medical, Surgical and Aesthetic Dermatology and Sexually Transmitted Diseases, the Maltese Association of Dermatology and Venereology and the Lithuanian Dermatological Society and was awarded the Medal in Silver by the Wroclaw Medical University, Poland and the Medal of the Rappaport Faculty of Medicine, Technion – Israel Institute of Technology.
He received numerous national and international awards, including the Skin Cancer Prize, the Oskar Gans Prize for Research in Dermatology, the European Dermatology Research Fellowship, the Felix Wankel Animal Protection Research Prize, the “Beauty Care Prize” for excellent Dermatological Research, the “Geroulanos Prize” for History of Medicine, the Paul Gerson Unna Prize on Immunology, the “Liérac Research Award” for Skin Aging Research, the Springer Prize for Dermatology, the Honorary Membership of the patients` charity Deutsche Interessengemeinschaft Akne inversa e.V., and the Open Health Alliance Excellence Award. His Departments have been decorated with the title “Germany land of ideas – place of excellence” for the work on skin stem cells.
Prof. Zouboulis has an extensive publication record with a h-index of 99 (Google Scholar), personal impact factor 2039, and 36000 citations.